Ontology highlight
ABSTRACT:
SUBMITTER: Signori A
PROVIDER: S-EPMC7641098 | biostudies-literature | 2020 Nov
REPOSITORIES: biostudies-literature
Signori Alessio A Saccà Francesco F Lanzillo Roberta R Maniscalco Giorgia Teresa GT Signoriello Elisabetta E Repice Anna Maria AM Annovazzi Pietro P Baroncini Damiano D Clerico Marinella M Binello Eleonora E Cerqua Raffaella R Mataluni Giorgia G Perini Paola P Bonavita Simona S Lavorgna Luigi L Zarbo Ignazio Roberto IR Laroni Alice A Pareja-Gutierrez Lorena L La Gioia Sara S Frigeni Barbara B Barcella Valeria V Frau Jessica J Cocco Eleonora E Fenu Giuseppe G Clerici Valentina Torri VT Sartori Arianna A Rasia Sarah S Cordioli Cinzia C Stromillo Maria Laura ML Di Sapio Alessia A Pontecorvo Simona S Grasso Roberta R Barone Stefania S Barrilà Caterina C Russo Cinzia Valeria CV Esposito Sabrina S Ippolito Domenico D Landi Doriana D Visconti Andrea A Sormani Maria Pia MP
Neurology(R) neuroimmunology & neuroinflammation 20200814 6
<h4>Objective</h4>Cladribine tablets were tested against placebo in randomized controlled trials (RCTs). In this study, the effectiveness of cladribine vs other approved drugs in patients with relapsing-remitting MS (RRMS) was compared by matching RCT to observational data.<h4>Methods</h4>Data from the pivotal trial assessing cladribine tablets vs placebo (CLARITY) were propensity score matched to data from the Italian multicenter database i-MuST. This database included 3,150 patients diagnosed ...[more]